Two independent surveys of 200 rheumatologists and dermatologists have unveiled recent developments <\/p>\n
To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever. <\/p>\n
CosentyxDermatologicalsEli LillyNovartisPharmaceuticalResearchTaltzUSA <\/p>\n
Access The Pharma Letter's latest news free for 7 days <\/p>\n<\/p>\n
PLUS... you can receive the Pharma Letter headlines and news roundup email free forever <\/p>\n
Click here to take a free trial <\/p>\n
Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year <\/p>\n<\/p>\n
Click here to subscribe <\/p>\n
<\/p>\n
More: <\/p>\n
In psoriasis, report shows Taltz closing in on Cosentyx - The Pharma Letter (registration)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Two independent surveys of 200 rheumatologists and dermatologists have unveiled recent developments To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Continue reading